Compare Occidental Petroleum Corporation (OXY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs Sana Biotechnology Inc — how do they compare? Occidental Petroleum Corporation trades at $60.22 (market cap $60.26B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Occidental Petroleum Corporation is far larger — about 72× Sana Biotechnology Inc's market cap, and Occidental Petroleum Corporation pays a 1.86% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Occidental Petroleum Corporation for 92 Days and Sana Biotechnology Inc for 23 Days on average.
| OXY | SANA | |
|---|---|---|
Market Cap | $60.26B | $836.71M |
Volume | 11,718,920 | 4,507,444 |
Sector | Energy | Health |
52-Week High | $66.24 | $5.92 |
52-Week Low | $38.92 | $2.68 |
Typical Hold Time | 92 Days | 23 Days |
Enterprise Value | $79.02B | $749.96M |
Dividend Yield | 1.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $60.52, up 3.97% in the last session, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.40 surpassing the $1.83 expectation. Financial health is supported by a strong net income margin of 30.32% and an ROE of 21.46%, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Analyst consensus is a Buy with a $71.40 price target, and a dividend of $0.28 is scheduled for payment in October 2026.
OXY presents a positive outlook driven by earnings beats, debt reduction efforts, and analyst optimism, but faces risks from volatile oil prices and declining revenue trends. Investment appeal hinges on execution of cash flow targets and oil market stability, with current valuation metrics like a P/E of 17.78 appearing reasonable relative to growth prospects.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
